For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
TBI pathogenesis is a complex process that affects millions of individuals around the world. TBI typically originates from an initial injury, related directly to an external impact to the brain, and followed by the gradual development of secondary pathogenesis. The secondary pathogenesis consists of a molecular, chemical, and inflammatory cascade, involving the release of excitatory neurotransmitters, and results in either temporary or permanent neurological deficits.1
The complex pathophysiology of TBI hinders the development of rapid biofluid-based diagnostic tests for the management of patients with TBI, including those in the intensive care unit or emergency room. Axonal injury is the most common type of brain injury due to the extended length of axonal fiber tracts. However, TBI-induced damage may affect neuronal bodies, dendrites, and synapses as well as other types of neural cells such as astroglial cells and oligodendrocytes. Therefore, a panel of neuronal injury biomarkers may be a potential solution to access the multi-component pathology of brain injury.2
Learn more about the role of biomarkers in TBI and acute neuronal injury research from Professor Kaj Blennow, chief physician at the Institute of Neuroscience and Physiology, University of Gothenburg. Prof. Blennow talks us through promising biomarkers (GFAP, UCHL1, S100B, NFL) that can identify neuronal damage and predict outcomes after the concussion. He further focuses on neurofilament light (NFL) biomarker and highlights that the NFL can potentially serve as a blood biomarker for acute neuronal damage.
Blood biomarkers for TBI and acute neuronal injury may have several clinical applications: to diagnose neuronal injuries after concussions in sports and to predict outcomes after TBI or cardiac arrest, accompanied by hypoxic brain injury.
Get reproducible, batch-to-batch consistency using recombinant monoclonal antibodies and proteins for your TBI research. These are some of our best-selling products.
|Gene name||Target name||Location of injury||Recommended abID|
|UCHL1||PGP9.5||Neuronal cell body2||ab108986|
|ENO2||NSE||Neuronal cell body2||ab220216|
|Product name||Species||Expression system||abID|
Recombinant human PGP9.5 protein (Active)
Recombinant Human GFAP protein
Recombinant Human S100 beta protein
Recombinant Human 68kDa Neurofilament/NF-L protein (His tag)
Recombinant Human Myelin Basic Protein (Tagged)
Recombinant Human NSE protein
Recombinant human BDNF protein
Recombinant Human PSD95 protein
Our Neuroinflammation Marker (BDNF, ICAM1, TREM2, GFAP, TNF alpha, Iba1) Antibody Panel - Human (ab263462) combines recombinant monoclonal antibodies against several neuroinflammation targets in 10 μL sampler vials, providing you access to antibodies in a convenient and cost-effective format.
Our ELISA kits are sensitive, reliable and suitable for a wide range of samples, including plasma, cerebrospinal fluid, and tissue extract. Our SimpleStep ELISA® kits allow you to achieve results within 90-minutes.
Check out our FirePlex Human Key Cytokines - Immunoassay Panel (ab243549), which contains recombinant monoclonal antibodies against key human cytokines and allows you to run a 17-plex assay.